期刊文献+

应用变性高效液相色谱对EPHX1基因进行分型 被引量:1

Detection of EPHX1 rs4653436 polymorphism by denaturing high performance liquid chromatography
暂未订购
导出
摘要 目的基于变性高效液相色谱技术,建立一种快速检测环氧化物水解酶(EPHX1)基因多态位点rs4653436(G>A)的基因分型方法。方法标准酚-氯仿法提取275例健康人外周血基因组DNA,应用聚合酶链反应/变性高效液相色谱(PCR/DHPLC)方法检测rs4653436(G>A)位点基因型。结果275例无关个体中,基因型GG、GA和AA分别有176例、93例和6例,各占64.0%、33.8%和2.2%,G和A等位基因的频率分别为80.9%和19.1%。结论变性高效液相色谱技术检测EPHX1rs4653436基因型简便、准确,为研究rs4653436多态性与华法林用量个体差异的相关性打下基础。 Objective To develop a genotyping assay for detection of EPHX1 rs4653436 polymorphism by using denaturing high performance liquid chromatography(DHPLC). Methods Genome DNA samples of 275 normal subjects were extracted by phenolchloroform method from peripheral blood. A PCR/DHPLC genotyping assay was developed to detect the genotypes of EPHX1 rs4653436 in the subjects. Results Among the 275 individuals,the numbers of GG,GA and AA genotype were 176,93 and 6,with the frequencies of 64.0% ,33.8% and 2.2% ,respectively. The frequencies of G and A allele were 80.9% and 19.1% ,respectively. Conclusion The DHPLC assay for detection of EPHX1 rs4653436 polymorphism is simple and accurate,which is helpful for the further study of the association of the EPHX1 rs4653436 polymorphism with individual warfarin dose requirement.
出处 《重庆医学》 CAS CSCD 北大核心 2010年第7期780-781,I0001,共3页 Chongqing medicine
基金 贵州省科技厅基金资助项目(黔科合J字[2008]2296号)
关键词 环氧化物水解酶 基因多态性 华法林 microsomal epoxide hydrolase gene polymorphism warfarin
  • 相关文献

参考文献12

  • 1Loebstein R,Vecsler M, Kurnik D, et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9[J]. Clin Pharmacol Ther,2005,77(5) :365.
  • 2Morisseau C, Hammock BD. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles [J] Annu Rev Pharmacol Toxicol, 2005,45 : 311.
  • 3Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism[J]. Hum Genet,2007,121(1) :23.
  • 4Siest G,Jeannesson E,Berrahmoune H, et al. Pharmacogenomics and drug response in cardiovascular disorders [J]. Pharmacogenomics, 2004,36 (7) : 779.
  • 5Richard DH, Sandra CK, Bruce HM, et al, Pharmacogenomics in endocrinology[J]. J Clin Endocrinol Metab, 2002,87(6) :2495.
  • 6吴非飞,梅霞,罗羽慧.华法林预防非瓣膜病房颤血栓栓塞[J].重庆医学,2005,34(3):371-372. 被引量:1
  • 7Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1-rationale and perspectives [J]. Thromb Res,2007,120(1) :1.
  • 8Bodin L,Verstuyft C,Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase ( VKORC1 ) genotypes as determinants of acenocoumarol sensitivity[J]. Blood,2005,106(1) :135.
  • 9Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen[J]. Blood, 2005,106 (7) : 2329.
  • 10Huang SW,Chen HS,Wang XQ,et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose:a prospective study in Chinese patients[J]. Pharmacogenet Genomics,2009,19(3) :226.

二级参考文献3

  • 1Muramatsu H,Shimura T. Incidence of cerebral thromboembolice infarction associated with paroxysmal and persistent or permanent atial fibrillation[J].JACC,2000,35(suppl A):103.
  • 2Connolly SJ,Laupacis A,Gen M.Canadian atrial fibrillation anticoagulation (CAFA) study [J].Jam Coll Cardiol,1991,18(2):527.
  • 3杨清波,焦丽萍.华法林抗凝应注意的问题[J].临床荟萃,2000,15(2):94-95. 被引量:5

同被引文献8

  • 1Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism[J]. Hum Gen- et, 2007,121(1):23-24.
  • 2Chenhsu RY, Chiang SC, Chou MH, et al. Long-term treatment with warfarin in Chinese population[J]. Ann Pharmacother, 2000, 34(12): 1395-1401.
  • 3Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interin- dividual variability in anticoagulant response to warfarin[J]. Pharma- cogenomics J, 2003, 3(4): 202-214.
  • 4Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen[J]. Blood, 2005,106(7):2329-2933.
  • 5Huang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients[J]. Pharmacogenet Genomics, 2009, 19(3):226-234.
  • 6Sconce EA, Daly AK, Khan TI, et al. APOE genotype makes a small contribution to warfarin dose requirements[J]. Pharmacogenet Ge- nomics, 2006, 16(8):609-611.
  • 7Loebstein R, Vecsler M, Kurnik D, et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9[J]. Clin Pharmacol Ther, 2005,77(5):365-372.
  • 8Wang TL, Li HL, Tjong WY, et al. Genetic factors contribute to patient-specific warfarin dose for Han Chinese[J]. Clin Chim Acta, 2008,396(1-2): 76-79.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部